This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
by Ekta Bagri
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
QUREPositive Net Change RHHBYPositive Net Change PTCTPositive Net Change WVEPositive Net Change
biotechs medical pharmaceuticals
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
by Ekta Bagri
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
QUREPositive Net Change PTCTPositive Net Change WVEPositive Net Change
biotechs medical pharmaceuticals
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
by Zacks Equity Research
Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year, while reaffirming full-year guidance despite a CFO transition.
HRMYPositive Net Change NVAXPositive Net Change LQDAPositive Net Change
biotechnology biotechs pharmaceuticals
Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?
by Ekta Bagri
NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, strengthening its nephrology portfolio.
NVSPositive Net Change VRTXPositive Net Change TVTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
by Zacks Equity Research
Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.
MRKPositive Net Change NVSPositive Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
by Zacks Equity Research
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
LLYPositive Net Change ATAINegative Net Change LQDAPositive Net Change KNSAPositive Net Change
biotechs pharmaceuticals
GSK Discontinues Development of Camlipixant for Refractory Chronic Cough
by Zacks Equity Research
GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug remains in a phase IIb study for irritable bowel syndrome.
GSKPositive Net Change NBIXPositive Net Change AMRNPositive Net Change LQDAPositive Net Change
biotechs
MRNA Advances Cancer Pipeline With New Immunotherapy Study
by Zacks Equity Research
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
MRNAPositive Net Change MRKPositive Net Change IMTXPositive Net Change
biotechs
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.
VKTXPositive Net Change EWTXPositive Net Change ABSIPositive Net Change
biotechs medical
AWHL vs. MYGN: Which Women's Health Diagnostics Stock is Better Now?
by Debanjana Dey
Aspira and Myriad Genetics take different approaches to women's health diagnostics, but which stock looks more compelling now? Let's dive in.
MYGNNegative Net Change AWHLPositive Net Change
biotechnology biotechs cancer medical medical-devices oncology-screening